4 ms·
>People are asking too much of Alphabet. Alphabet could easily choose not to publish anything. To be honest, I'm shocked that they do publish. Yeah, no. No one
by COGlory 2y ago
>People are asking too much of Alphabet. Alphabet could easily choose not to publish anything. To be honest, I'm shocked that they do publish.
Yeah, no. No one would be working at Alphabet if they didn't publish this work. Which means the work would never get done to begin with.
- CamelCaseName 2y agoPerhaps when Alphafold was just starting, but now they are the undisputed king. Would you rather publish or work on the cutting edge?
- hehdhdjehehegwv 2y agoLook at Apple’s ML efforts which are the result of not supporting publishing cutting edge research. Or, better yet, ask Siri and you’ll get the answer.
- deleted 2y ago[deleted]
- mupuff1234 2y agoSo where else would they work?
- guyomes 2y agoIn academy for example, including the publicly funded institute mentioned in the article (European Molecular Biology Laboratory’s European Bioinformatics Institute). Also, there is a blog page on the deep mind website where they cite "millions of researcher" around the world using alphafold [1]. Some of those institutions might be happy to develop the new alphafold. On the other hand, even in academy, scientific articles are not always the best examples of open and reproducible research [2,3]. And in computer science, it is common for articles to be more focused on algorithms than on implementations. [1]: https://deepmind.google/impact/meet-the-scientists-using-alphafold/ https://deepmind.google/impact/meet-the-scientists-using-alp... [2]: https://en.wikipedia.org/wiki/Reproducibility https://en.wikipedia.org/wiki/Reproducibility [3]: https://en.wikipedia.org/wiki/Replication_crisis https://en.wikipedia.org/wiki/Replication_crisis
- anon84873628 2y agoJust like no one would be working at <innumerable other AI or pharmaceutical companies>. Or the rest of closed source Google? Yeah, no.
- COGlory 2y agoI'm a structural biologist and I work at an AI pharmaceutical company. Even we still publish. We publish both methodologies in peer reviewed journals, and patents.